Search of biomarkers related to the therapeutic effect of sublingual immunotherapy with epigenome analysis

Search of biomarkers related to the therapeutic effect of sublingual immunotherapy with epigenome analysis - Epigenome analysis of the therapeutic effect of sublingual immunotherapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023910

Enrollment

Registered

2016-09-05

Start date

2016-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

sublingual immunotherapy for cedar pollinosis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects who wish to treatment of sublingual immunotherapy in health care in the adaptation's cedar pollen sublingual immunotherapy of IgE antibody-positive against cedar pollen

Exclusion criteria

Exclusion criteria: Exclusion criteria included severe asthma cases or malignant tumors, such as collagen disease merger example, it is contraindicated patients with sublingual immunotherapy therapeutic agent Shidatoren.

Design outcomes

Primary

Measure	Time frame
Epigenome analysis of before and after treatment	—

Countries

Japan

Contacts

Public ContactMinoru Gotoh

Nippon Medical School Tamanagayama Hospital Otorhinolaryngology

m.gotoh@nms.ac.jp042-371-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026